Frontlight ResearchEarly access
SuspendedPhase 1/2
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Key facts
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1/2
- People taking part
- 30 people enrolled
- Started
- 1 Nov 2019
- Ended
- 30 Dec 2023
- Type of study
- Interventional
- Treatments tested
- Chemotherapy
- Immunotherapy
- IMRT
- Record updated
- 3 January 2024
- Why it stopped
- Inadequate patient enrollment
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients who personally provided written consent for participation in the study
- Treatment-naive patients with rectal cancer, in whom the inferior margin of the tumor is at a distance of 10 cm or less from the AV before CRT
- Histologically confirmed adenocarcinoma of rectum (non-metastatic, >T2N0 or low T2N0 rectal cancer) not eligible for up-front organ preservation surgery as deemed by multidisciplinary evaluation
- Patients with the ECOG performance status of 0 or 1 at the time of enrollment
- Women of childbearing potential who consent to practicing contraception during the period from giving informed consent to at least 23 weeks after the last dose of therapy
- Male patients who consent to practicing contraception during the period from giving informed consent to at least 31 weeks after the last dose of the study drug
- Patients must have acceptable organ and marrow function as defined below:; Absolute neutrophil count (ANC) >1,500/uL Hg > 8.0 g/dL; if blood transfusion is performed for achieving adequate hemoglobin level, the level should stay above goal for at least 1 week after transfusion Platelets >100,000/uL Total bilirubin <1.5X normal institutional limits aspartate aminotransferase (AST) (SGOT) / alanine aminotransferase (ALT)(SGPT) < 3X upper limit of normal Creatinine <1.5X upper limit of normal or creatinine clearance (CrCL)>50 by Cockcroft-Gault
Who cannot take part
- Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease
- Patients requiring treatment with systemic corticosteroids or immunosuppressants or who have received these treatments within 14 days before enrollment in the study
- Patients who are positive for any of the following: HIV1 antibody, HIV2 antibody, HTLV1 antibody
- Patients with recurrent rectal cancer or a history of pelvic radiation
- Patients with a history of inflammatory bowel disease
- Patients with a history of pneumonitis or interstitial lung disease
- Patients with a history of thyroid dysfunction
- Patients with significant unstable mental diseases or other medical diseases that may interfere with the safety of the subjects, obtaining informed consent, or compliance with the procedures for the clinical study
- Patients with a history or finding of cardiovascular risk
- Patients who are pregnant or lactating or who may be pregnant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a open-label, single-arm study to investigate the safety and efficacy of Total neoadjuvant chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy in patients with rectal cancer.
The group in the trial
- radiotherapy, chemotherapy and PD1 inhibitorTreatment being tested
Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
Treatment: Chemotherapy, Immunotherapy, and IMRT
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Short Course Radiotherapy With Total Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
- Record updated
- 3 January 2024